Thrombotic thrombocytopenic purpura preceding systemic lupus erythematous

Carmen Pilar Simeon-Aznar, Rafael Cuenca-Luque, Vicente Fonollosa-Pla, Jose Angel Bosch-Gil

Abstract
The case of a patient admitted with thrombotic thrombocytopenic purpura nine years after developing systemic lupus erythematous (SLE) is reported. Thrombotic thrombotic purpura associated with SLE has been described on other occasions, but in most patients the diagnosis of SLE precedes that of thrombotic thrombocytopenic purpura. The unusual sequence and the chronological separation of the two diseases is emphasised.

Thrombotic thrombocytopenic purpura is a rare clinical syndrome characterised by the presence of microangiopathic haemolytic anaemia, thrombocytopenic purpura, neurological abnormalities, fever, and renal dysfunction. In most patients there is no known aetiological agent or related underlying disease. On rare occasions, thrombotic thrombocytopenic purpura has been described in association with systemic lupus erythematosus (SLE). A relation between SLE and thrombotic thrombocytopenic purpura has not been shown; however, similar clinical features may be observed in the two diseases. Chronologically, thrombotic thrombocytopenic purpura presents in patients previously diagnosed with SLE. An inverse sequence of events is rare. A patient who presented with thrombotic thrombocytopenic purpura and who then developed SLE nine years later is described in this paper.

Case report
A 30 year old woman with no relevant medical history was admitted in January 1980 with general weakness, headache, jaundice, and petechiae. Physical examination also revealed skin and mucous membrane pallor and hepatosplenomegaly. A chest radiograph was normal. Laboratory data included severe anaemia with haemoglobin 70 g/l (normal <120 g/l), packed cell volume 0.2, abundant schistocytes, platelet count 17x10^9/l (normal 150-450x10^9/l), direct bilirubin 136.8 µmol/l (normal 6-84 µmol/l), haptoglobin 0 g/l, and reticulocyte count 250x10^9/l (normal <75x10^9/l). Coagulation tests were normal. Coombs' and sucrose lysis tests were negative. A test for antinuclear antibodies was positive at a titre of 1/2560 with a speckled pattern; antibodies to double stranded DNA could now be seen at 139 U/l (normal <15 U/l). Anticardiolipin antibodies and lupus anticoagulant were negative. Sucrose lysis and Coombs' tests were negative. A renal biopsy sample revealed diffuse proliferative glomerulonephritis. A diagnosis of SLE with renal involvement was made and treatment with methylprednisolone (60 mg/day) and bolus cyclophosphamide (15 mg/kg/day) was initiated. The patient improved with this treatment.

Discussion
The diagnosis of thrombotic thrombocytopenic purpura is usually based on the clinico-biological syndrome (microangiopathic haemolytic anaemia, thrombocytopenic purpura, neuro-
logical abnormalities, fever and renal dysfunction) presented by the patients. There are several similarities between the clinical features of SLE and thrombotic thrombocytopenic purpura which present certain difficulties at the time of diagnosis, although in most patients differential elements point to one pathological disease or the other. In SLE, microangiopathic anaemia, usually associated with diffuse vasculitis or malignant hypertension, may rarely be detected. Negativity or normality of SLE immunological markers (antibodies to DNA, Coombs' test or complement) support the diagnosis of thrombotic thrombocytopenic purpura in doubtful instances, although non-SLE associated positive antinuclear antibodies have been found in some patients with thrombotic thrombocytopenic purpura. The finding of characteristic pathological features in a gingival biopsy sample confirms the diagnosis of thrombotic thrombocytopenic purpura, but their absence does not rule it out. In a recent review, only 39% of biopsies performed gave specific results. The clinical and analytical manifestations presented by our patient on the first admission, the remission obtained with plasmapheresis, and the lack of criteria for the diagnosis of SLE confirm the diagnosis of thrombotic thrombocytopenic purpura.

Triggering factors of thrombotic thrombocytopenic purpura include toxic agents, infections and drugs, although in most patients (90%) there is no apparent cause. The association of SLE and thrombotic thrombocytopenic purpura is rare. In the review of Ridolfi and Bell of 250 patients with thrombotic thrombocytopenic purpura, only three met the presently accepted criteria for SLE. Isolated patients with thrombotic thrombocytopenic purpura and SLE were later described. In the series of Levine and Shearn, 34 of 151 patients (23%) presented signs and symptoms suggestive of SLE. Clinical information available on these patients was incomplete and did not fulfil the American Rheumatism Association 1982 revised criteria for the diagnosis of SLE. There are only three reported patients in whom the diagnosis of thrombotic thrombocytopenic purpura preceded the development of SLE. However, the diagnosis of SLE in these patients was based on pathological findings (Libman-Sacks endocarditis, glomerulonephritis, peri-adventitial splenic fibrosis), which suggested a 'lupus-type' disease; the strict application of present criteria places the diagnosis in doubt. On her second admission, our patient, apart from presenting no signs of thrombotic thrombocytopenic purpura, fulfilled sufficient criteria for the diagnosis of SLE (arthritis, leucopenia, diffuse proliferative glomerulonephritis, high antinuclear antibody titres and increased antibodies to double stranded DNA).

To establish a pathogenic relation between thrombotic thrombocytopenic purpura and SLE, various hypotheses have been suggested; however, the precise mechanism is still to be defined. Patients with SLE may present alterations of coagulation and thus be at greater risk of thrombosis. Some patients with SLE who developed thrombotic thrombocytopenic purpura had a previous history of thrombophlebitis. On the other hand, an immunological connection between the two diseases has not been identified, as patients with SLE who present with thrombotic thrombocytopenic purpura during a clinical or immunological flare of their disease have also been described. The development of thrombotic thrombocytopenic purpura during remission of SLE has also been reported. It has recently been suggested that thrombotic thrombocytopenic purpura may play a pathogenic part in central nervous system alterations in SLE. A necropsy study of 50 patients with neurological manifestations of SLE showed pathological central nervous system alterations in 50% of patients. In the final stages of their disease, 14 patients presented a clinical syndrome of thrombotic thrombocytopenic purpura; in half of these pathological thrombotic thrombocytopenic purpura changes in the central nervous system (occlusion of arterioles and capillaries with platelet-fibrin thrombi, segmental subendothelial hyalin deposits, and arteriolar microaneurysms) were observed. In ten of the remaining patients, cerebral infarctions secondary to embolism of cardiac origin (Libman-Sacks endocarditis in five, chronic valvulitis in two, heart mural thrombus in two), were reported. No vasculitic lesions were observed in any of the patients. These authors suggested that thrombotic thrombocytopenic purpura lesions and endocarditis were common pathogenic factors in central nervous system alterations in SLE. No coagulation studies were performed in most of these patients; however, many may have had an 'antiphospholipid syndrome'.

We believe that our patient differs from others previously reported, not only in the unusual chronological sequence of presentation, but also in the difficulty encountered in establishing a correlation between thrombotic thrombocytopenic purpura and SLE, given the long period of time in which the patient was asymptomatic and the clinical presentation of the two diseases in the same patient.

The authors thank Christine O'Hara for her help with the English translation of this paper.

8 Alpert L I. Thrombotic thrombocytopenic purpura and
Thrombotic thrombocytopenic purpura preceding systemic lupus erythematosus.

C P Simeon-Aznar, R Cuenca-Luque, V Fonollosa-Pla and J A Bosch-Gil

doi: 10.1136/ard.51.3.396

Updated information and services can be found at:
http://ard.bmj.com/content/51/3/396

These include:

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/